• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COX-2/PGES/EP 信号通路中的 SNPs 与卡培他滨引起的严重手足综合征的风险相关。

SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.

机构信息

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出版信息

Cancer Chemother Pharmacol. 2020 Apr;85(4):785-792. doi: 10.1007/s00280-020-04053-9. Epub 2020 Mar 19.

DOI:10.1007/s00280-020-04053-9
PMID:32193619
Abstract

PURPOSE

Capecitabine is a widely used 5-fluorouracil oral prodrug. Hand-foot syndrome (HFS), one of the most common adverse events of capecitabine, impacts patients' quality of life seriously. The pathogenesis of HFS remains unclear but was usually considered as a type of inflammation conducted by cyclooxygenase-2 (COX-2). The COX-2/PGES/EP signaling pathway plays an important role in the inflammatory reaction. We hypothesized that the single nucleotide polymorphisms (SNPs) in this pathway may be associated with the risk of HFS induced by capecitabine.

PATIENTS AND METHODS

Using DNA from blood samples of 225 patients, we genotyped 19 SNPs in 6 core genes (COX-2, PGES, EP1, EP2, EP3, and EP4). Common Terminology Criteria for Adverse Events version 3.0 was used to grade hand-foot syndrome. We used logistic regression analysis to evaluate the correlations between genotype variants and occurrence of HFS. The cumulative incidence of HFS was assessed by Kaplan-Meier analysis.

RESULTS

Among the 225 participants, 58.6% (132/225) patients developed into HFS, including 41.3% (93/225) grade 1 HFS, 10.2% (23/225) grade 2 HFS and 7.1% (16/225) grade 3 HFS. Multivariate logistic regression analysis showed the AG/GG genotype of rs3810255 to be associated with a significantly higher risk of grade 2/3 HFS, while the AG/AA genotype of rs17131450 to be associated with a significantly lower risk of grade 2/3 HFS (OR = 3.646, P = 0.011; and OR = 0.266, P = 0.036; respectively).

CONCLUSION

Our study showed that rs3810255 AG/GG genotypes and rs17131450 GG genotypes to be associated with high risk of capecitabine-induced HFS.

摘要

目的

卡培他滨是一种广泛应用的 5-氟尿嘧啶口服前体药物。手足综合征(HFS)是卡培他滨最常见的不良反应之一,严重影响患者的生活质量。HFS 的发病机制尚不清楚,但通常被认为是一种由环氧化酶-2(COX-2)介导的炎症。COX-2/PGES/EP 信号通路在炎症反应中起重要作用。我们假设该通路中的单核苷酸多态性(SNP)可能与卡培他滨引起的 HFS 风险相关。

患者和方法

使用来自 225 名患者的血液样本中的 DNA,我们对 6 个核心基因(COX-2、PGES、EP1、EP2、EP3 和 EP4)中的 19 个 SNP 进行了基因分型。采用常见不良事件术语标准 3.0 对 HFS 进行分级。我们使用逻辑回归分析评估基因型变异与 HFS 发生之间的相关性。通过 Kaplan-Meier 分析评估 HFS 的累积发生率。

结果

在 225 名参与者中,58.6%(132/225)的患者发生 HFS,包括 41.3%(93/225)的 1 级 HFS、10.2%(23/225)的 2 级 HFS 和 7.1%(16/225)的 3 级 HFS。多变量逻辑回归分析显示 rs3810255 的 AG/GG 基因型与 2/3 级 HFS 的发生风险显著相关,而 rs17131450 的 AG/AA 基因型与 2/3 级 HFS 的发生风险显著相关(OR=3.646,P=0.011;和 OR=0.266,P=0.036)。

结论

我们的研究表明,rs3810255 的 AG/GG 基因型和 rs17131450 的 GG 基因型与卡培他滨引起的 HFS 风险增加相关。

相似文献

1
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.COX-2/PGES/EP 信号通路中的 SNPs 与卡培他滨引起的严重手足综合征的风险相关。
Cancer Chemother Pharmacol. 2020 Apr;85(4):785-792. doi: 10.1007/s00280-020-04053-9. Epub 2020 Mar 19.
2
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.MTHFR 和 TYMS 多态性可预测转移性乳腺癌患者卡培他滨引起的手足综合征。
Cancer Commun (Lond). 2019 Oct 11;39(1):57. doi: 10.1186/s40880-019-0399-z.
3
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.手足综合征及其预防药物——吡哆醇的预测因子:卡培他滨致手足综合征的随机临床试验。
JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.
4
Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.TYMS 多态性预测中国结直肠癌患者卡培他滨相关性手足综合征
Cancer Res Treat. 2021 Jul;53(3):724-732. doi: 10.4143/crt.2020.457. Epub 2020 Dec 2.
5
Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.卡培他滨治疗的癌症患者手足综合征:马来西亚癌症中心对其发生率、影响及相关危险因素的研究。
Support Care Cancer. 2024 May 14;32(6):345. doi: 10.1007/s00520-024-08490-7.
6
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.局部用双氯芬酸预防卡培他滨相关性手足综合征:一项双盲随机对照试验。
J Clin Oncol. 2024 May 20;42(15):1821-1829. doi: 10.1200/JCO.23.01730. Epub 2024 Feb 27.
7
Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.卡培他滨诱发手足综合征的可能途径。
Chem Res Toxicol. 2016 Oct 17;29(10):1591-1601. doi: 10.1021/acs.chemrestox.6b00215. Epub 2016 Sep 28.
8
Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.采用 Markov 建模方法评估卡培他滨所致手足综合征患者报告的严重程度。
Cancer Chemother Pharmacol. 2020 Sep;86(3):435-444. doi: 10.1007/s00280-020-04128-7. Epub 2020 Aug 27.
9
Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).口服胱氨酸和茶氨酸对术后接受以卡培他滨为基础的辅助化疗的结直肠癌患者的疗效:一项多机构、随机、双盲、安慰剂对照的II期试验(JORTC-CAM03)
Support Care Cancer. 2020 Aug;28(8):3649-3657. doi: 10.1007/s00520-019-05205-1. Epub 2019 Dec 6.
10
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.塞来昔布可预防Ⅱ期和Ⅲ期结直肠癌患者卡培他滨相关手足综合征:一项单中心、前瞻性、随机 III 期试验结果。
Ann Oncol. 2012 May;23(5):1348-1353. doi: 10.1093/annonc/mdr400. Epub 2011 Sep 22.

引用本文的文献

1
Elucidating Celecoxib's Preventive Effect in Capecitabine-Induced Hand-Foot Syndrome Using Medical Natural Language Processing.利用医学自然语言处理阐明塞来昔布在卡培他滨诱导的手足综合征中的预防作用。
JCO Clin Cancer Inform. 2025 Aug;9:e2500096. doi: 10.1200/CCI-25-00096. Epub 2025 Aug 12.
2
Imrecoxib: Advances in Pharmacology and Therapeutics.依美昔布:药理学与治疗学的新进展。
Drug Des Devel Ther. 2024 May 22;18:1711-1725. doi: 10.2147/DDDT.S464485. eCollection 2024.
3
Predictive factors for the development of capecitabine-induced hand-foot syndrome: a retrospective observational cohort study.

本文引用的文献

1
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.改良 XELIRI(卡培他滨联合伊立替康)对比 FOLFIRI(亚叶酸钙、氟尿嘧啶、伊立替康),二者均联合或不联合贝伐珠单抗,作为转移性结直肠癌的二线治疗(AXEPT):一项多中心、开放标签、随机、非劣效性、3 期临床试验。
Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.
2
Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.卡培他滨所致手足综合征预防策略的临床证据。
Int J Cancer. 2018 Jun 15;142(12):2567-2577. doi: 10.1002/ijc.31269. Epub 2018 Feb 2.
3
卡培他滨所致手足综合征发生的预测因素:一项回顾性观察队列研究。
Ann Med Surg (Lond). 2023 Nov 7;86(1):73-77. doi: 10.1097/MS9.0000000000001487. eCollection 2024 Jan.
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.手足综合征及其预防药物——吡哆醇的预测因子:卡培他滨致手足综合征的随机临床试验。
JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.
4
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.卡培他滨辅助治疗新辅助化疗后的乳腺癌。
N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.
5
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.S-1 对比卡培他滨用于转移性结直肠癌一线治疗的随机 III 期临床试验:荷兰结直肠癌研究组 SALTO 研究。
Ann Oncol. 2017 Jun 1;28(6):1288-1293. doi: 10.1093/annonc/mdx122.
6
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.XELOX(或 FOLFOX)诱导一线治疗转移性结直肠癌后的单药卡培他滨维持治疗:疗效和安全性的随机临床试验。
Ann Oncol. 2016 Jun;27(6):1074-1081. doi: 10.1093/annonc/mdw101. Epub 2016 Mar 2.
7
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.卡培他滨联合奥沙利铂对比氟尿嘧啶/亚叶酸钙作为 III 期结肠癌辅助治疗:NO16968 随机对照 III 期临床试验的最终结果。
J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31.
8
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.卡培他滨相关性手足综合征的预防性治疗:AIO 生活质量工作组的一项多中心 III 期随机试验,比较 MAPISAL 乳膏和尿素乳膏。
J Clin Oncol. 2015 Aug 1;33(22):2444-9. doi: 10.1200/JCO.2014.60.4587. Epub 2015 Jun 29.
9
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.卡培他滨联合奥沙利铂辅助治疗 D2 胃切除术后胃癌(CLASSIC):一项开放标签、随机、3 期临床试验的 5 年随访结果。
Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15.
10
Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.化疗引起的手足综合征和甲改变:临床特征、病因、发病机制和治疗的综述。
J Am Acad Dermatol. 2014 Oct;71(4):787-94. doi: 10.1016/j.jaad.2014.03.019. Epub 2014 May 1.